Manchester University has signed a five-year agreement with AstraZeneca to develop personalised healthcare treatments for cancer patients.
The two will harness clinical bioinformatics as part of trial to capture data in real time. The project, for which AstraZeneca is providing £11.5m ($17.69m), will be led by a team of researchers based at Manchester’s Cancer Research Centre, and conducted in partnership with the Christie NHS Foundation Trust.
Andrew Hughes, professor of experimental cancer medicine at the research centre, said: “Patient insight is key to our understanding of new cancer drugs. The information we get from patients about their experiences of taking new drugs is key to shaping our risk:benefit assessment. AstraZeneca has long supported the UK science base and this latest collaboration with the Manchester Cancer Research Centre will enable the patients to share their insights with investigators and sponsors more effectively and efficiently than today – enabling a more informed assessment.”
